Free shipping on all orders over $ 500

DCC-2036

Cat. No. M1702
DCC-2036 Structure
Synonym:

Rebastinib

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
2mg USD 50  USD50 In stock
5mg USD 70  USD70 In stock
10mg USD 115  USD115 In stock
25mg USD 195  USD195 In stock
50mg USD 300  USD300 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

DCC-2036, known as the lead "switch-control" inhibitor, potently inhibits both unphosphorylated and phosphorylated ABL1 by inducing a type II inactive conformation, and retains efficacy against the majority of clinically relevant CML-resistance mutants, including T315I. DCC-2036 inhibits BCR-ABL1 (T315I)-expressing cell lines, prolongs survival in mouse models of T315I mutant CML and B-lymphoblastic leukemia, and inhibits primary patient leukemia cells expressing T315I in vitro and in vivo, supporting its clinical development in TKI-resistant Ph (+) leukemia.

Customer Product Validations & Biological Datas
Source PLoS One (2013). Figure 1. DCC-2036
Method Immunoblotting
Cell Lines EOL-1 cells
Concentrations 6 nM
Incubation Time 24 h
Results DCC-2036 effectively decreased the phosphorylated-PDGFRa in BaF3 cells expressing FIP1L1-PDGFRa T674I mutant in a concentration- and time-dependent manner while the total protein level of PDGFRa was not affected.
Protocol (for reference only)
Cell Experiment
Cell lines Ba/F3 cells or primary Ph+ leukemia cells
Preparation method Cell Proliferation Assays
Ba/F3 cells (3×103 cells/well) or primary Ph+ leukemia cells (5×104 cells/well) were plated in triplicate in 96-well plates containing test compounds. After 72h, viable cells were quantified by resazurin (O’Brien et al., 2000) or MTT (Roumiantsev et al., 2002) assay as described. Results represent an average of at least three independent experiments.
Concentrations 0.1~10 mM
Incubation time 72 h
Animal Experiment
Animal models Allograft and retroviral BM transduction/transplantation mouse models of BCR-ABL1-induced leukemia
Formulation 0.5% CMC/1% Tween-80
Dosages 100 mg/kg once daily
Administration oral gavage
Chemical Information
Molecular Weight 553.59
Formula C30H28FN7O3
CAS Number 1020172-07-9
Solubility (25°C) DMSO 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] O'Hare et al. Blood. The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

[2] Eide et al. Cancer Res. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

[3] Chan et al. Cancer Cell. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

Related Src-bcr-Abl Products
Osteogenic Growth Peptide (10-14)

Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity.

Abl Cytosolic Substrate

Abl Cytosolic Substrate is a substrate for Abelson tyrosine kinase (Abl ).

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH

Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH is a high-affinity pentapeptide to bind to the src SH2 domain (IC50≈1 µM).

p60c-src substrate II

p60c-src substrate II is an efficient pentapeptide substrate for the tyrosine kinase pp60c-src.

Caffeic acid-pYEEIE

Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain.

  Catalog
Abmole Inhibitor Catalog




Keywords: DCC-2036, Rebastinib supplier, Src-bcr-Abl, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.